12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EV-077: Additional Phase IIa data

Additional data from the first cohort of 32 Type II diabetics in a double-blind, German Phase IIa trial showed that twice-daily 300 mg oral EV-077 met the primary efficacy endpoint of inhibiting platelet aggregation vs. placebo (p=0.001). EV-077 also improved both macrovascular (43% vs. 20%) and microvascular (108% vs. 25%) endothelial function from baseline to day 29 vs. placebo. Additionally, EV-077 reduced peak albuminuira after exercise from baseline to day 29 vs. placebo in 21...

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >